Conference Call with JK Lakshmi Cement Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Supriya Lifescience announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: In the fourth quarter of FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 16.4 % year-over-year increase, reaching Rs 184.11 crore compared to Rs 158.18 crore in Q4FY24. EBITDA for Q4FY25 stood at Rs 67.58 crore, with an EBITDA Margin of 36.7 %, as opposed to an EBITDA of Rs 55.5 crore in Q4FY24 with an EBITDA margin of 35.1%. This marks an improvement of 162 bps YoY. Profit after Tax for Q4FY25 stood at Rs 50.38 crore, with a growth of 38.4% compared to Rs 36.40 crore in Q4FY24. The PAT Margin stood at 27.4% in Q4FY25, compared to 23.0% in Q4FY24 FY25 Financial Highlights: In FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 22% year-over-year increase, reaching Rs 696.48 crore compared to Rs 570.37 crore in FY24. EBITDA for FY25 stood at Rs 260.80 crore, with an EBITDA Margin of 37.4 %, as opposed to an EBITDA of Rs 172.98 crore in FY24 with an EBITDA margin of 30.3%. This marks an improvement of 712 bps YoY. Profit after Tax for FY25 stood at Rs 187.96 crore, with a growth of 57.8% compared to Rs 119.11 crore in FY24. The PAT Margin stood at 27.0% in FY25, compared to 20.9% in FY24. Satish Wagh, Chairman and Whole Time Director, Supriya Lifescience commenting on the results, said, “FY25 has been a landmark year for Supriya Lifescience, reflecting the strength of our diversified product portfolio, resilient global operations, and consistent focus on operational excellence. We achieved our highest-ever annual revenue of Rs 697 crore, up 22% year-on-year, and delivered an EBITDA of Rs 261 crore with a robust margin of 37.4%. In Q4FY25, revenue grew by 16.4% to Rs 184.11 crore, while PAT rose by 38.4% to Rs 50.38 crore, supported by improved margins. Our strategic focus on high-value therapeutic segments, deeper penetration in regulated markets, and strengthened backward integration continue to drive our performance. We remain committed to building on this momentum to deliver sustainable growth, foster innovation, and create long-term value for all stakeholders.” Result PDF
Conference Call with Medplus Health Services Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Copper company Hindustan Copper announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from Operations stood at Rs 731 crore for Q4FY25 compared to Rs 565 crore for Q4FY24 PAT stood at Rs 190.4 crore for Q4FY25 compared to Rs 124.31 crore for Q4FY24 FY25 Financial Highlights: The Profit Before Tax (PBT) has surged by 54% to Rs 633.51 crore in FY 2024-25 from Rs 410.43 crore in FY 2023-24. HCL has recorded its highest ever Revenue from Operation of Rs 2070.97 crore in FY 2024-25, reflecting a robust year-on-year (YoY) increase by 21% percent from Rs 1717 crore in FY 2023-24. The Company has clocked an increase in Profit After Tax (PAT) by 42%o to Rs 468.53 crore from Rs 295.41 crore in FY 2023-24. The EBITDA margin achieved has been a healthy 38% in FY 2024-25 as compared to 34% in tlne previous year, showing an increase of 4 bps. Result PDF
Auto Parts & Equipment company Rico Auto Industries announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Total Revenue declined by 0.5% (Rs 549 crore vs Rs 551 crore) EBITDA declined by 12.8% (Rs 54 crore vs Rs 62 crore) EBITDA Margin dropped by 140 basis points (9.9% vs 11.3%) Net Profit declined by 54.8% (Rs 7.36 crore vs Rs 16.29 crore) Net Profit Margin dropped by 161 basis points (1.3% vs 3.0%) Earnings Per Share (EPS) decreased by 55.0% (Rs 0.54 vs Rs 1.20) FY25 Financial Highlights: Total Revenue increased by 2.3% (Rs 2,225 crore vs Rs 2,174 crore) EBITDA declined by 15.0% (Rs 201 crore vs Rs 237 crore) EBITDA Margin dropped by 184 basis points (9.0% vs 10.9%) Net Profit declined by 45.0% (Rs 21.41 crore vs Rs 38.94 crore) Net Profit Margin dropped by 83 basis points (1.0% vs 1.8%) Earnings Per Share (EPS) decreased by 45.1% (Rs 1.58 vs Rs 2.88) Result PDF
Conference Call with Entero Healthcare Solutions Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.